Global Opioid-Induced Constipation Market Size Is Projected To Reach US$ 3315 Million By 2027, From US$ 2415 Million In 2020, At A CAGR Of 4.6% During 2021-2027

QY Research has made a brilliant attempt to elaborately and meticulously analyze the global Opioid-Induced Constipation market in its latest report. All of the market forecasts presented in the report are authentic and reliable.

Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives. Global Opioid-Induced Constipation key players include Sanofi, Bayer, Purdue Pharm, etc. Global top three manufacturers hold a share over 45%. North America is the largest market, with a share about 55%, followed by Europe, and Asia-Pacific, both have a share about 35 percent. In terms of product, Lubiprostone is the largest segment, with a share about 5%. And in terms of application, the largest application is Pharmacy, followed by Hospital, etc. Market Analysis and Insights: Global Opioid-Induced Constipation Market The global Opioid-Induced Constipation market size is projected to reach US$ 3315 million by 2027, from US$ 2415 million in 2020, at a CAGR of 4.6% during 2021-2027.

Request Sample Report and Full Report TOC: 

https://www.qyresearch.com/sample-form/form/3266055/global-opioid-induced-constipation-market

The Essential Content Covered in the Global Opioid-Induced Constipation Market Report :

* Top Key Company Profiles.
* Main Business and Rival Information
* SWOT Analysis and PESTEL Analysis
* Production, Sales, Revenue, Price and Gross Margin
* Market Share and Size

Top Players of Opioid-Induced Constipation Market are Studied: Takeda Pharmaceuticals, Bayer, Sanofi, Mallinckrodt, Salix (Bausch Health), AstraZeneca, Progenics Pharmaceuticals, Purdue Pharm, Nektar Therapeutics, Daiichi Sankyo, Prestige, GSK, Shionogi

The report provides a 6-year forecast (2021-2027) assessed based on how the Opioid-Induced Constipation market is predicted to grow in major regions like USA, Europe, Japan, China, India, Southeast Asia, South America, South Africa, Others.

Segmentation by Type:  Methylnaltrexone Bromide, Lubiprostone, Naloxegol, Others

Segmentation by Application:  Hospital, Pharmacy, Other

Get Full Customize report or for any Special Discount visit@  
https://www.qyresearch.com/customize-request/form/3266055/global-opioid-induced-constipation-market
Reasons to Buy this Report:

Industry Size & Forecast: Estimations on the global Opioid-Induced Constipation industry size on the basis of value and volume are provided in this part of the report
Study on Key Industry Trends: This section offers deep insights into the prevailing and upcoming Opioid-Induced Constipation trends
Segmental Analysis: Here, the report has examined the high-growth segments including product type, application, and end-users, taking into account their CAGR, share, and size
Future Prospects: Current Opioid-Induced Constipation developments and future opportunities estimated to emerge in the Opioid-Induced Constipation industry are looked into in this portion of the study
Geography-wise Analysis: The authors of the report have studied the regions having growth potential to help companies plan their future investments
Study on Competitive Landscape: The industry experts have offered thorough information about the strategic tactics adopted by the industry participants to consolidate their position. This assessment will help the players to strategize their activities in future.
Buy Now this Report at USD(3350):

https://www.qyresearch.com/settlement/pre/ed3532fc491a5feed84406487442adec,0,1,global-opioid-induced-constipation-market

TOC

1 Opioid-Induced Constipation Market Overview
1.1 Opioid-Induced Constipation Product Overview
1.2 Opioid-Induced Constipation Market Segment by Type
1.2.1 Methylnaltrexone Bromide
1.2.2 Lubiprostone
1.2.3 Naloxegol
1.2.4 Others
1.3 Global Opioid-Induced Constipation Market Size by Type
1.3.1 Global Opioid-Induced Constipation Market Size Overview by Type (2016-2027)
1.3.2 Global Opioid-Induced Constipation Historic Market Size Review by Type (2016-2021)

1.3.2.1 Global Opioid-Induced Constipation Sales Breakdown in Volume by Type (2016-2021)

1.3.2.2 Global Opioid-Induced Constipation Sales Breakdown in Value by Type (2016-2021)

1.3.2.3 Global Opioid-Induced Constipation Average Selling Price (ASP) by Type (2016-2021)
1.3.3 Global Opioid-Induced Constipation Forecasted Market Size by Type (2022-2027)

1.3.3.1 Global Opioid-Induced Constipation Sales Breakdown in Volume by Type (2022-2027)

1.3.3.2 Global Opioid-Induced Constipation Sales Breakdown in Value by Type (2022-2027)

1.3.3.3 Global Opioid-Induced Constipation Average Selling Price (ASP) by Type (2022-2027)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Opioid-Induced Constipation Sales Breakdown by Type (2016-2021)
1.4.2 Europe Opioid-Induced Constipation Sales Breakdown by Type (2016-2021)
1.4.3 Asia-Pacific Opioid-Induced Constipation Sales Breakdown by Type (2016-2021)
1.4.4 Latin America Opioid-Induced Constipation Sales Breakdown by Type (2016-2021)
1.4.5 Middle East and Africa Opioid-Induced Constipation Sales Breakdown by Type (2016-2021) 2 Global Opioid-Induced Constipation Market Competition by Company
2.1 Global Top Players by Opioid-Induced Constipation Sales (2016-2021)
2.2 Global Top Players by Opioid-Induced Constipation Revenue (2016-2021)
2.3 Global Top Players Opioid-Induced Constipation Price (2016-2021)
2.4 Global Top Manufacturers Opioid-Induced Constipation Manufacturing Base Distribution, Sales Area, Product Type
2.5 Opioid-Induced Constipation Market Competitive Situation and Trends
2.5.1 Opioid-Induced Constipation Market Concentration Rate (2016-2021)
2.5.2 Global 5 and 10 Largest Manufacturers by Opioid-Induced Constipation Sales and Revenue in 2020
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Opioid-Induced Constipation as of 2020)
2.7 Date of Key Manufacturers Enter into Opioid-Induced Constipation Market
2.8 Key Manufacturers Opioid-Induced Constipation Product Offered
2.9 Mergers & Acquisitions, Expansion 3 Opioid-Induced Constipation Status and Outlook by Region
3.1 Global Opioid-Induced Constipation Market Size and CAGR by Region: 2016 VS 2021 VS 2026
3.2 Global Opioid-Induced Constipation Historic Market Size by Region
3.2.1 Global Opioid-Induced Constipation Sales in Volume by Region (2016-2021)
3.2.2 Global Opioid-Induced Constipation Sales in Value by Region (2016-2021)
3.2.3 Global Opioid-Induced Constipation Sales (Volume & Value) Price and Gross Margin (2016-2021)
3.3 Global Opioid-Induced Constipation Forecasted Market Size by Region
3.3.1 Global Opioid-Induced Constipation Sales in Volume by Region (2022-2027)
3.3.2 Global Opioid-Induced Constipation Sales in Value by Region (2022-2027)
3.3.3 Global Opioid-Induced Constipation Sales (Volume & Value), Price and Gross Margin (2022-2027) 4 Global Opioid-Induced Constipation by Application
4.1 Opioid-Induced Constipation Market Segment by Application
4.1.1 Hospital
4.1.2 Pharmacy
4.1.3 Other
4.2 Global Opioid-Induced Constipation Market Size by Application
4.2.1 Global Opioid-Induced Constipation Market Size Overview by Application (2016-2027)
4.2.2 Global Opioid-Induced Constipation Historic Market Size Review by Application (2016-2021)

4.2.2.1 Global Opioid-Induced Constipation Sales Breakdown in Volume, by Application (2016-2021)

4.2.2.2 Global Opioid-Induced Constipation Sales Breakdown in Value, by Application (2016-2021)

4.2.2.3 Global Opioid-Induced Constipation Average Selling Price (ASP) by Application (2016-2021)
4.2.3 Global Opioid-Induced Constipation Forecasted Market Size by Application (2022-2027)

4.2.3.1 Global Opioid-Induced Constipation Sales Breakdown in Volume, by Application (2022-2027)

4.2.3.2 Global Opioid-Induced Constipation Sales Breakdown in Value, by Application (2022-2027)

4.2.3.3 Global Opioid-Induced Constipation Average Selling Price (ASP) by Application (2022-2027)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Opioid-Induced Constipation Sales Breakdown by Application (2016-2021)
4.3.2 Europe Opioid-Induced Constipation Sales Breakdown by Application (2016-2021)
4.3.3 Asia-Pacific Opioid-Induced Constipation Sales Breakdown by Application (2016-2021)
4.3.4 Latin America Opioid-Induced Constipation Sales Breakdown by Application (2016-2021)
4.3.5 Middle East and Africa Opioid-Induced Constipation Sales Breakdown by Application (2016-2021) 5 North America Opioid-Induced Constipation by Country
5.1 North America Opioid-Induced Constipation Historic Market Size by Country
5.1.1 North America Opioid-Induced Constipation Sales in Volume by Country (2016-2021)
5.1.2 North America Opioid-Induced Constipation Sales in Value by Country (2016-2021)
5.2 North America Opioid-Induced Constipation Forecasted Market Size by Country
5.2.1 North America Opioid-Induced Constipation Sales in Volume by Country (2022-2027)
5.2.2 North America Opioid-Induced Constipation Sales in Value by Country (2022-2027) 6 Europe Opioid-Induced Constipation by Country
6.1 Europe Opioid-Induced Constipation Historic Market Size by Country
6.1.1 Europe Opioid-Induced Constipation Sales in Volume by Country (2016-2021)
6.1.2 Europe Opioid-Induced Constipation Sales in Value by Country (2016-2021)
6.2 Europe Opioid-Induced Constipation Forecasted Market Size by Country
6.2.1 Europe Opioid-Induced Constipation Sales in Volume by Country (2022-2027)
6.2.2 Europe Opioid-Induced Constipation Sales in Value by Country (2022-2027) 7 Asia-Pacific Opioid-Induced Constipation by Region
7.1 Asia-Pacific Opioid-Induced Constipation Historic Market Size by Region
7.1.1 Asia-Pacific Opioid-Induced Constipation Sales in Volume by Region (2016-2021)
7.1.2 Asia-Pacific Opioid-Induced Constipation Sales in Value by Region (2016-2021)
7.2 Asia-Pacific Opioid-Induced Constipation Forecasted Market Size by Region
7.2.1 Asia-Pacific Opioid-Induced Constipation Sales in Volume by Region (2022-2027)
7.2.2 Asia-Pacific Opioid-Induced Constipation Sales in Value by Region (2022-2027) 8 Latin America Opioid-Induced Constipation by Country
8.1 Latin America Opioid-Induced Constipation Historic Market Size by Country
8.1.1 Latin America Opioid-Induced Constipation Sales in Volume by Country (2016-2021)
8.1.2 Latin America Opioid-Induced Constipation Sales in Value by Country (2016-2021)
8.2 Latin America Opioid-Induced Constipation Forecasted Market Size by Country
8.2.1 Latin America Opioid-Induced Constipation Sales in Volume by Country (2022-2027)
8.2.2 Latin America Opioid-Induced Constipation Sales in Value by Country (2022-2027) 9 Middle East and Africa Opioid-Induced Constipation by Country
9.1 Middle East and Africa Opioid-Induced Constipation Historic Market Size by Country
9.1.1 Middle East and Africa Opioid-Induced Constipation Sales in Volume by Country (2016-2021)
9.1.2 Middle East and Africa Opioid-Induced Constipation Sales in Value by Country (2016-2021)
9.2 Middle East and Africa Opioid-Induced Constipation Forecasted Market Size by Country
9.2.1 Middle East and Africa Opioid-Induced Constipation Sales in Volume by Country (2022-2027)
9.2.2 Middle East and Africa Opioid-Induced Constipation Sales in Value by Country (2022-2027) 10 Company Profiles and Key Figures in Opioid-Induced Constipation Business
10.1 Takeda Pharmaceuticals
10.1.1 Takeda Pharmaceuticals Corporation Information
10.1.2 Takeda Pharmaceuticals Introduction and Business Overview
10.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
10.1.4 Takeda Pharmaceuticals Opioid-Induced Constipation Products Offered
10.1.5 Takeda Pharmaceuticals Recent Development
10.2 Bayer
10.2.1 Bayer Corporation Information
10.2.2 Bayer Introduction and Business Overview
10.2.3 Bayer Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
10.2.4 Bayer Opioid-Induced Constipation Products Offered
10.2.5 Bayer Recent Development
10.3 Sanofi
10.3.1 Sanofi Corporation Information
10.3.2 Sanofi Introduction and Business Overview
10.3.3 Sanofi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
10.3.4 Sanofi Opioid-Induced Constipation Products Offered
10.3.5 Sanofi Recent Development
10.4 Mallinckrodt
10.4.1 Mallinckrodt Corporation Information
10.4.2 Mallinckrodt Introduction and Business Overview
10.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
10.4.4 Mallinckrodt Opioid-Induced Constipation Products Offered
10.4.5 Mallinckrodt Recent Development
10.5 Salix (Bausch Health)
10.5.1 Salix (Bausch Health) Corporation Information
10.5.2 Salix (Bausch Health) Introduction and Business Overview
10.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
10.5.4 Salix (Bausch Health) Opioid-Induced Constipation Products Offered
10.5.5 Salix (Bausch Health) Recent Development
10.6 AstraZeneca
10.6.1 AstraZeneca Corporation Information
10.6.2 AstraZeneca Introduction and Business Overview
10.6.3 AstraZeneca Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
10.6.4 AstraZeneca Opioid-Induced Constipation Products Offered
10.6.5 AstraZeneca Recent Development
10.7 Progenics Pharmaceuticals
10.7.1 Progenics Pharmaceuticals Corporation Information
10.7.2 Progenics Pharmaceuticals Introduction and Business Overview
10.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
10.7.4 Progenics Pharmaceuticals Opioid-Induced Constipation Products Offered
10.7.5 Progenics Pharmaceuticals Recent Development
10.8 Purdue Pharm
10.8.1 Purdue Pharm Corporation Information
10.8.2 Purdue Pharm Introduction and Business Overview
10.8.3 Purdue Pharm Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
10.8.4 Purdue Pharm Opioid-Induced Constipation Products Offered
10.8.5 Purdue Pharm Recent Development
10.9 Nektar Therapeutics
10.9.1 Nektar Therapeutics Corporation Information
10.9.2 Nektar Therapeutics Introduction and Business Overview
10.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
10.9.4 Nektar Therapeutics Opioid-Induced Constipation Products Offered
10.9.5 Nektar Therapeutics Recent Development
10.10 Daiichi Sankyo
10.10.1 Company Basic Information, Manufacturing Base and Competitors
10.10.2 Opioid-Induced Constipation Product Category, Application and Specification
10.10.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2016-2021)
10.10.4 Main Business Overview
10.10.5 Daiichi Sankyo Recent Development
10.11 Prestige
10.11.1 Prestige Corporation Information
10.11.2 Prestige Introduction and Business Overview
10.11.3 Prestige Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
10.11.4 Prestige Opioid-Induced Constipation Products Offered
10.11.5 Prestige Recent Development
10.12 GSK
10.12.1 GSK Corporation Information
10.12.2 GSK Introduction and Business Overview
10.12.3 GSK Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
10.12.4 GSK Opioid-Induced Constipation Products Offered
10.12.5 GSK Recent Development
10.13 Shionogi
10.13.1 Shionogi Corporation Information
10.13.2 Shionogi Introduction and Business Overview
10.13.3 Shionogi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
10.13.4 Shionogi Opioid-Induced Constipation Products Offered
10.13.5 Shionogi Recent Development 11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Opioid-Induced Constipation Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Opioid-Induced Constipation Industrial Chain Analysis
11.4 Opioid-Induced Constipation Market Dynamics
11.4.1 Industry Trends
11.4.2 Market Drivers
11.4.3 Market Challenges
11.4.4 Market Restraints 12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Opioid-Induced Constipation Distributors
12.3 Opioid-Induced Constipation Downstream Customers 13 Research Findings and Conclusion 14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach

14.1.1.1 Research Programs/Design

14.1.1.2 Market Size Estimation

14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source

14.1.2.1 Secondary Sources

14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer

 
 

Contact US:
QY Research, INC.
17890 Castleton,
Suite 218,
City of industry, CA – 91748
USA: +1 626 295 2442
Email: enquiry@qyresearch.com
Web: http://www.qyresearch.com

About Us

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become a brand of quality assurance in the consulting industry. 

This release was published on openPR.